- Home
- COE vs VOR Comparison
COE vs VOR Comparison
Compare COE & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- VOR
- Stock Information
- Founded
- COE 2011
- VOR 2015
- Country
- COE Singapore
- VOR United States
- Employees
- COE N/A
- VOR N/A
- Industry
- COE Other Consumer Services
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- VOR Health Care
- Exchange
- COE Nasdaq
- VOR Nasdaq
- Market Cap
- COE 177.0M
- VOR 202.4M
- IPO Year
- COE 2016
- VOR 2021
- Fundamental
- Price
- COE $28.72
- VOR $2.76
- Analyst Decision
- COE
- VOR Buy
- Analyst Count
- COE 0
- VOR 7
- Target Price
- COE N/A
- VOR $3.77
- AVG Volume (30 Days)
- COE 20.4K
- VOR 46.8M
- Earning Date
- COE 08-22-2025
- VOR 08-07-2025
- Dividend Yield
- COE N/A
- VOR N/A
- EPS Growth
- COE N/A
- VOR N/A
- EPS
- COE N/A
- VOR N/A
- Revenue
- COE $59,490,000.00
- VOR N/A
- Revenue This Year
- COE N/A
- VOR N/A
- Revenue Next Year
- COE N/A
- VOR N/A
- P/E Ratio
- COE N/A
- VOR N/A
- Revenue Growth
- COE 91.87
- VOR N/A
- 52 Week Low
- COE $11.84
- VOR $0.13
- 52 Week High
- COE $34.74
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- COE 51.58
- VOR 78.77
- Support Level
- COE $27.98
- VOR $2.25
- Resistance Level
- COE $31.50
- VOR $3.29
- Average True Range (ATR)
- COE 2.40
- VOR 0.52
- MACD
- COE -0.70
- VOR 0.18
- Stochastic Oscillator
- COE 21.31
- VOR 82.52
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.